Ziphius LLC
June 17, 2025
Company Presentation
Infectious Disease and Vaccines
153A
Ziphius, a Belgium/US-based private biotech company, is advancing a next-generation platform utilizing self-amplifying RNA (saRNA) and lipid nanoparticles (LNPs) to develop first and best in class medicines for infectious diseases, rare diseases, and oncology. Since our founding in 2019, we have raised $43M and are now preparing to secure an additional $50M in 2025 to accelerate the development of our programs and reach our first clinical milestones. With a dedicated team of 65 professionals based in Belgium and the US (New York), Ziphius is committed to developing first- and best-in-class RNA medicines. Pipeline: 1. Chlamydia Trachomatis vaccine 2. Pan-Corona vaccine 3. Cystic Fibrosis therapy Milestones Recent preclinical studies data in Pigs: -Superior Humoral and CMI responses -Ongoing NHP studies
Company HQ City:
New York
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2019
Lead Product in Development:
Chlamydia Trachomatis Vaccine
Pancorona Vaccine
Cystic fibrosis therapy
CEO
Chris Cardon - CEO
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
-
When you expect your next catalyst update?
Non Human Primates study result
What is your next catalyst (value inflection) update?
March, 2025
Website
https://ziphius.org/
Primary Speaker
.png)
)
)
){kind=logo}
){kind=logo}
){kind=logo}